Gastroesophageal Reflux Disease (GERD)

Gastroenterology
12
Pipeline Programs
5
Companies
18
Clinical Trials
1
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
1
0
9
1
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
2100%
+ 10 programs with unclassified modality

On Market (1)

Approved therapies currently available

U
RABEPRAZOLE SODIUMApproved
rabeprazole sodium
Unknown Company
oral2013

Competitive Landscape

4 companies ranked by most advanced pipeline stage

E
EisaiChina - Liaoning
7 programs
1
6
Rabeprazole ERPhase 31 trial
Rabeprazole ERPhase 31 trial
Rabeprazole sodiumPhase 31 trial
Rabeprazole sodiumPhase 31 trial
Rabeprazole sodiumPhase 31 trial
+2 more programs
Active Trials
NCT00838526Completed240Est. Dec 2009
NCT00839306Completed240Est. Jan 2010
NCT00658775Completed1,069Est. Jan 2010
+2 more trials
Takeda
TakedaTOKYO, Japan
2 programs
1
PantoprazolePhase 3Small Molecule5 trials
Correlation of Oropharyngeal Pepsin and Gastroesophageal (GE) RefluxN/A1 trial
Active Trials
NCT01091805Completed143Est. Oct 2013
NCT01132638Completed713Est. Jun 2012
NCT00449813Terminated40Est. Nov 2008
+3 more trials
Ironwood Pharmaceuticals
2 programs
2
IW-3718Phase 31 trial
IW-3718Phase 31 trial
Active Trials
NCT03561883CompletedEst. Nov 2020
NCT03561090TerminatedEst. Nov 2020
AstraZeneca
AstraZenecaCAMBRIDGE, United Kingdom
1 program
1
AZD3355Phase 21 trial
Active Trials
NCT00394472Completed244Est. Jun 2007

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
TakedaPantoprazole
TakedaPantoprazole
TakedaPantoprazole
Ironwood PharmaceuticalsIW-3718
Ironwood PharmaceuticalsIW-3718
TakedaPantoprazole
EisaiRabeprazole ER
EisaiRabeprazole ER
EisaiRabeprazole sodium
EisaiRabeprazole sodium
EisaiRabeprazole sodium
TakedaPantoprazole
TakedaPantoprazole
TakedaPantoprazole
TakedaPantoprazole

Showing 15 of 18 trials with date data

Clinical Trials (18)

Total enrollment: 10,290 patients across 18 trials

NCT00449813TakedaPantoprazole

The CONQUEST-Study. Evaluation of Clinical Endpoints for Treatment-induced Changes in GERD-related Symptoms (BY1023/NL511)

Start: Mar 2007Est. completion: Nov 200840 patients
Phase 4Terminated
NCT00325676TakedaPantoprazole

Comparison of the Classical Healing Concept With the Complete Remission Concept After Treatment With Pantoprazole in Adult Patients With Erosive GERD (Gastroesophageal Reflux Disease) (BY1023/M3-342)

Start: Jun 2006639 patients
Phase 4Completed
NCT00261339TakedaPantoprazole

Determination of a Questionnaire After Treatment With Pantoprazole at Full Dose and Half Dose in Adult Patients With Symptoms of Acid Reflux (Gastroesophageal Reflux Disease) (BY1023/UK-506)

Start: Aug 2005300 patients
Phase 4Completed
NCT03561883Ironwood PharmaceuticalsIW-3718

Trial of IW-3718 for 8 Weeks in Patients With Persistent Gastroesophageal Reflux Disease (GERD) Receiving Proton Pump Inhibitors (PPIs)

Start: Sep 2018Est. completion: Nov 2020
Phase 3Completed
NCT03561090Ironwood PharmaceuticalsIW-3718

A Trial of IW-3718 for 8 Weeks in Patients With Persistent Gastroesophageal Reflux Disease (GERD) Receiving Proton Pump Inhibitors (PPIs)

Start: Jun 2018Est. completion: Nov 2020
Phase 3Terminated
NCT01132638TakedaPantoprazole

Pantoprazole Magnesium 40 mg Versus Esomeprazole 40 mg in Patients With Erosive Gastroesophageal Reflux Disease

Start: Aug 2011Est. completion: Jun 2012713 patients
Phase 3Completed
NCT00838526EisaiRabeprazole ER

Rabeprazole Extended-Release 50 mg vs. Ranitidine 150 mg for Maintenance of Healed Erosive Gastroesophageal Reflux Disease (GERD)

Start: Aug 2008Est. completion: Dec 2009240 patients
Phase 3Completed
NCT00839306EisaiRabeprazole ER

Rabeprazole Extended Release 50 mg Versus Ranitidine 150 mg for Maintenance of Healed Erosive Gastroesophageal Reflux Disease (GERD)

Start: Aug 2008Est. completion: Jan 2010240 patients
Phase 3Completed
NCT00658775EisaiRabeprazole sodium

Rabeprazole Extended-Release, 50 mg, Versus Esomeprazole, 40 mg, for Healing and Symptomatic Relief of Moderate to Severe Erosive Gastroesophageal Reflux Disease (GERD)

Start: Feb 2008Est. completion: Jan 20101,069 patients
Phase 3Completed
NCT00658528EisaiRabeprazole sodium

Rabeprazole Extended-Release 50 mg Versus Esomeprazole 40 mg for Healing and Symptomatic Relief of Moderate to Severe Erosive Gastroesophageal Reflux Disease (GERD)

Start: Feb 2008Est. completion: Jan 20101,061 patients
Phase 3Completed
NCT00658632EisaiRabeprazole sodium

Rabeprazole Extended-Release 50 mg Versus Esomeprazole 40 mg for Healing and Symptomatic Relief of Mild to Moderate Erosive Gastroesophageal Reflux Disease (GERD)

Start: Feb 2008Est. completion: Sep 20091,397 patients
Phase 3Completed
NCT00336219TakedaPantoprazole

Symptom Assessment in Adult Patients With Erosive GERD (Gastroesophageal Reflux Disease) or enGERD (Endoscopic-negative GERD) After Treatment With Pantoprazole (BY1023/M3-343)

Start: Aug 2006Est. completion: Apr 2007628 patients
Phase 3Completed
NCT00312806TakedaPantoprazole

Effect of Pantoprazole on the Symptoms of Acid Reflux Disease in Adult Patients (BY1023/M3-341)

Start: May 2006Est. completion: Jul 20072,000 patients
Phase 3Completed
NCT00163306TakedaPantoprazole

Efficacy of Pantoprazole in Patients Older Than 18 Years Who Have Symptoms of Acid Reflux (Gastroesophageal Reflux Disease) (BY1023/M3-339)

Start: May 20051,200 patients
Phase 3Completed
NCT00161096TakedaPantoprazole

On-Demand Use of Pantoprazole: Determinants for Chronic Use of Acid Suppressive Medication

Start: Mar 2004Est. completion: Sep 2005276 patients
Phase 3Unknown
NCT00261300TakedaPantoprazole

Long-term Pantoprazole Trial in Patients With Symptoms of Chronic Acid Peptic Complaints (BY1023/VMG-708)

Start: Oct 2000Est. completion: Jul 2008100 patients
Phase 3Completed
NCT00394472AstraZenecaAZD3355

Symptom Improvements in Gastroesophageal Reflux Disease (GERD) Patients

Start: Nov 2006Est. completion: Jun 2007244 patients
Phase 2Completed
NCT01091805TakedaCorrelation of Oropharyngeal Pepsin and Gastroesophageal (GE) Reflux

Correlation of Oropharyngeal Pepsin and Gastroesophageal (GE) Reflux

Start: Dec 2008Est. completion: Oct 2013143 patients
N/ACompleted

Related Jobs in Gastroenterology

Specialty Representative, Gastroenterology – Minneapolis, Minnesota

AbbVie
Remote
7h ago

Key Account Director, Diagnostics and Research

Tempus
Remote
20h ago
$150K - $200K/yr

Experienced Clin Programmer

Johnson & Johnson
High Wycombe, Buckinghamshire, United Kingdom
20h ago

[Innovative Medicine] Director, Government Affairs and Policy Dept., Integrated Market Access Div.

Johnson & Johnson
Chiyoda, Tokyo, Japan
20h ago

Analyst Accounting

Johnson & Johnson
Suzhou, Jiangsu, China
20h ago

Lead Product Security Engineer

Johnson & Johnson
Danvers, Massachusetts, United States of America
20h ago
$94K - $152K/yr

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

9 late-stage (Phase 3) programs — potential near-term approvals
5 companies competing in this space

Related Indications

Hepatic Impairment(79)Gastroesophageal Reflux Disease(37)Irritable Bowel Syndrome(29)Gastroesophageal Reflux(27)Liver Transplantation(24)Celiac Disease(23)Hepatic Insufficiency(22)Liver Cirrhosis(22)Hepatic Encephalopathy(12)Gastrointestinal Tolerance(12)